Did Merck pay $3B too much for Cubist?

By |2017-04-25T18:03:51+00:00December 9th, 2014|Pharma News|

Merck ($MRK) may have to rethink its math on the Cubist ($CBST) buyout. Announcing the $9.5 billion transaction Monday, the company pointed to an earnings bump beginning in 2016. But later in the day, a U.S. court nixed all but one of the patents covering its top seller, Cubicin--and that patent expires in 2016. With [...]

Read More
Comments Off on Did Merck pay $3B too much for Cubist?

Merck Acquiring Cubist, Focusing On Hospital Care

By |2014-12-08T17:32:59+00:00December 8th, 2014|Uncategorized|

ig pharma Merck (NYSE:MRK) agreed to buy antibiotic specialist Cubist Pharmaceuticals (NASDAQ:CBST) Monday in a deal valued at $9.5 billion. Cubist soared 35% in the stock market today, while Merck dropped a fraction. Merck is acquiring Cubist for $102 a share in cash, yielding an equity value of $8.4 billion, plus $1.1 billion in net [...]

Read More
Comments Off on Merck Acquiring Cubist, Focusing On Hospital Care
Go to Top